{
  "context": {
    "rules": [
      "Rule1: If DrugX treats a rare disease, then DrugX gets priority review status.",
      "Rule2: DrugX treats a rare disease or DrugX addresses an unmet medical need.",
      "Rule3: If DrugX addresses an unmet medical need, then if the failure of DrugX demonstrating clinical efficacy to lead to meeting endpoints does not result in DrugX requiring additional studies, then DrugX qualifies for fast track designation.",
      "Rule4: DrugX attracts investor funding or DrugX does not have a viable commercial market.",
      "Rule5: If DrugX enters commercial production, then DrugX becomes available to patients.",
      "Rule6: DrugX enters commercial production or DrugX does not attract investor funding.",
      "Rule7: If DrugX faces manufacturing delays, then DrugX does not become available to patients.",
      "Rule8: DrugX receives insurance coverage or DrugX is a viable therapy.",
      "Rule9: DrugX demonstrates cost effectiveness or DrugX shows superiority to standard care.",
      "Rule10: If DrugX shows superiority to standard care, then DrugX does not receive insurance coverage.",
      "Rule11: If DrugX gets formulary inclusion, then DrugX does not receive insurance coverage.",
      "Rule12: If DrugX presents health economic data, then if DrugX demonstrates cost effectiveness, then DrugX gets formulary inclusion.",
      "Rule13: If DrugX conducts real-world evidence study, then DrugX presents health economic data.",
      "Rule14: DrugX demonstrates clinical efficacy or DrugX shows an acceptable safety profile.",
      "Rule15: If DrugX shows an acceptable safety profile, then DrugX is a viable therapy.",
      "Rule16: If DrugX meets all clinical trial endpoints, then DrugX is a viable therapy.",
      "Rule17: If DrugX passing phase 3 clinical trials does not lead to the scenario where if DrugX is not a viable therapy then DrugX receives FDA approval, then DrugX does not receive emergency use authorization.",
      "Rule18: If the failure of DrugX passing phase 3 clinical trials to lead to the scenario where if DrugX is not a viable therapy then DrugX receives FDA approval does not result in DrugX receiving emergency use authorization, then DrugX receives orphan drug status.",
      "Rule19: If DrugX is not a viable therapy, then DrugX has a viable commercial market."
    ],
    "facts": [
      "Fact1: DrugX faces manufacturing delays.",
      "Fact2: DrugX passes phase 3 clinical trials.",
      "Fact3: DrugX conducts real-world evidence study.",
      "Fact4: DrugX does not receive FDA approval.",
      "Fact5: DrugX does not get priority review status.",
      "Fact6: DrugX does not receive orphan drug status.",
      "Fact7: DrugX does not require additional clinical studies.",
      "Fact8: DrugX does not qualify for fast track designation."
    ]
  },
  "question": "DrugX is a viable therapy."
}